SHR-A1811 + PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer With HER2- Mutations
Conditions
Non-Small Cell Lung Cancer With HER2- Mutations
Trial Timeline
Jul 29, 2024 → Apr 1, 2027
NCT ID
NCT06430437About SHR-A1811 + PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
SHR-A1811 + PD-1/PD-L1 inhibitors、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Non-Small Cell Lung Cancer With HER2- Mutations. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06430437. Target conditions include Non-Small Cell Lung Cancer With HER2- Mutations.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06430437 | Phase 3 | Recruiting |
Competing Products
20 competing products in Non-Small Cell Lung Cancer With HER2- Mutations